| Old Articles: <Older 39011-39020 Newer> |
|---|
 |
The Motley Fool
November 11, 2009
Tim Beyers |
Why Oracle Must Fight Europe Evidence suggests that MySQL today is worth materially more than what Sun paid for it. Oracle CEO Larry Ellison has no choice but to fight for fair value, and that means fighting the European Commission's ruling.   |
The Motley Fool
November 11, 2009
Dave Mock |
A Big Upgrade for H.J. Heinz This bullish call comes from more than just one analyst. |
The Motley Fool
November 11, 2009 |
Today's 5-Star Movers Today's top-moving stocks from the Motley Fool five-star stock list: SMART Modular Technologies... Ameron International Corp... SuperGen, Inc... |
The Motley Fool
November 11, 2009
Chris Jones |
The Sun Is Setting on This Stock Despite its financial woes, Sunrise is still trying to accentuate the positives. In its most recent quarter, management highlighted the progress with its ongoing balance sheet restructuring. But it will have to claw its way out of debt. |
The Motley Fool
November 11, 2009
Robert Steyer |
Wynn: The Loosest Dividends in Town Wynn Resorts makes the rare move among gambling companies of offering a quarterly dividend. |
The Motley Fool
November 11, 2009
Robert Steyer |
Las Vegas Sands Seeks to Wow Macau The rumors underestimated what the casino company wants to raise via an IPO for its China gambling operation. |
The Motley Fool
November 11, 2009
Christopher Barker |
5 Top Coal Picks for the Next 20 Years While the coal market endures seismic shifts, the long-term outlook remains sound. |
The Motley Fool
November 10, 2009
Rich Smith |
Hey! Who's Flying This Thing? Unmanned aerial vehicles spread wings and take flight around the globe. Invest in this trend today. Move too slow, and it may fly away from you. |
The Motley Fool
November 10, 2009
Rick Aristotle Munarriz |
Analysts Have an Altitude Problem Shares of the recession-bucking travel website, Priceline, opened 12% higher -- and kept rising -- after delivering yet another better-than-expected quarter. |
The Motley Fool
November 10, 2009
Brian Orelli |
Small Acquisitions and the Road to Success Bristol-Myers is taking a different route to bulk up. It announced licensing of a phase 2 rheumatoid arthritis drug, ALD518, from privately held Alder Biopharmaceuticals. |
| <Older 39011-39020 Newer> Return to current articles. |
